ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept ...

Understanding how molecules interact is central to biology: from decoding how living organisms function to uncovering disease ...

Merck (MRK) on Monday announced positive results from the first two of three late-stage clinical trials evaluating the safety ...